A registrational trial of SG-001
Latest Information Update: 29 Jan 2026
At a glance
- Drugs SG-001-ADMA-Biologics (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
Most Recent Events
- 29 Jan 2026 New trial record
- 12 Jan 2026 According to an ADMA Biologics media release, submission of a pre-IND package for SG-001 to the FDA anticipated in 2026, which would potentially enable the Company to progress development of SG-001 directly into a registrational clinical trial.